Article Text

Download PDFPDF

LSO-089 Effectiveness of belimumab in systemic lupus erythematosus patients of a multicenter Spanish cohort
  1. Irene Altabás-González1,2,
  2. José María Pego-Reigosa1,2,
  3. Coral Mouriño-Rodriguez1,2,
  4. Norman Jiménez-Otero1,2,
  5. Andrea Hernández-Martín3,
  6. Judit Roman-Urgelles4,
  7. Ivette Casafont-Sole4,
  8. José Andrés Roman-Ivorra5,
  9. Marta De la Rubia-Navarro5,
  10. María Galindo-Izquierdo6,
  11. Tarek Salman-Montes7,
  12. Javier Narváez8,
  13. Paola Vidal-Montal8,
  14. María Jesús García-Villanueva9,
  15. Sandra Garrote-Corral9,
  16. María Ángeles Blázquez-Cañamero9,
  17. Carlos Marras-Fernández10,
  18. María Piqueras-García10,
  19. Julia Martínez-Barrio11,
  20. Marina Sánchez-Lucas11,
  21. Josefina Cortés-Hernández12,
  22. Eleonora Penzo12,
  23. Jaime Calvo-Alen13,
  24. Juan Ramón De Dios Jiménez de Aberásturi13,
  25. Belén Álvarez-Rodríguez13,
  26. Margarida Vasques Rocha13,
  27. Eva Tomero14,
  28. Raúl Menor-Almagro15,
  29. Myriam Gandía-Martínez15,
  30. José A Gómez-Puerta16,
  31. Beatriz Frade-Sosa16,
  32. Consuelo Ramos-Giráldez17,
  33. Carmen Trapero-Pérez17,
  34. Elvira Díez-Álvarez18,
  35. Clara Moriano18,
  36. Alejandro Muñoz-Jiménez19 and
  37. Íñigo Rúa-Figueroa3
  1. 1Rheumatology, Complejo Hospitalario universitario de Vigo, Spain
  2. 2Rheumatology, IRIDIS Group, Spain
  3. 3Rheumatology, Hospital Universitario de Gran Canaria Dr. Negrín, Spain
  4. 4Rheumatology, Hospital Universitario Germans Trias i Pujol, Spain
  5. 5Rheumatology, Hospital Universitario y Politécnico de la Fe, Spain
  6. 6Rheumatology, Hospital 12 de octubre, Spain
  7. 7Rheumatology, Hospital del Mar, Spain
  8. 8Rheumatology, Hospital Universitario de Bellvitge, Spain
  9. 9Rheumatology, Hospital Universitario Ramón y Cajal, Spain
  10. 10Rheumatology, Hospital Virgen de la Arrixaca de Murcia, Spain
  11. 11Rheumatology, Hospital General Universitario Gregorio Marañón, Spain
  12. 12Rheumatology, Hospital Universitario Valle d´ Hebrón, Spain
  13. 13Rheumatology, Hospital Universitario Araba, Spain
  14. 14Rheumatology, Hospital Universitario de La Princesa, Spain
  15. 15Rheumatology, Hospital Universitario de Jerez, Spain
  16. 16Rheumatology, Hospital Clinic de Barcelona, Spain
  17. 17Rheumatology, Hospital Universitario Nuestra Señora de Valme, Spain
  18. 18Rheumatology, Hospital Universitario de León, Spain
  19. 19Rheumatology, Hospital universitario Virgen del Rocío, Spain


Background To evaluate belimumab (BLM) effectiveness in SLE patients from a Spanish multicenter registry.

Methods A longitudinal retrospective multicenter cohort including SLE patients treated with belimumab. Data collection at baseline, 6, 12 months and in the last visit available. Changes in SLEDAI-2K; LLDAS and DORIS-2021 states and response according to physician were compared between visits; also changes in damage and glucocorticoids used. T-test was used for numerical variables and the Fisher’s test for categorical variables.

Results 324 patients: 295 (91%) females with a mean (±SD) age of 42.4 (±12.9) years. Mean follow-up was 3,8 (±2.7) years and mean time with BLM was 2.7 (±2.4) years. Baseline mean SLEDAI-2K was 10.4 (±5.25). BLM was initiated with another DMARD in 67.9% of patients.

SLEDAI-2K significantly reduced in all visits. Rates of LLDAS, DORIS and clinical response according to physician criteria, significantly increased from baseline to the successive evaluations. Anti-dsDNA antibodies and inflammatory markers (ESR, CRP), significantly decreased over the time. (table 1).

107 (45,9%) patients discontinued GC. Mean (±SD) prednisone dose was significantly reduce over the visits: 12.3 (±12.16) and 4.7 (±3.7) mg/day at baseline and in the last visit, respectively (table 1). Median (IQR) SDI score at the end of the observation period did not change from baseline visit: 0 (0–1) and 0 (0–1) (p=0.97). No chanfes in the percentage of patients with damage between the beginning and the end of the study: 47.5% (n=152) and 45.6% (n=99), respectively.

Conclusions Our data confirm belimumab efficacy in real world, reducing clinical and serological activity in the short and medium-term. BLM leads to high rates of LLDAS and DORIS at 6 months, that continue increasing over time. BLM has an important GC sparing effect and prevents organ damage accrual. BLM is useful to achieve the therapeutic goals of a T2T strategy.

Abstract LSO-089 Table 1

Clinical response and changes in GC dose

  • SLE
  • Rheumatology
  • Belimumab

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.